Pfizer

Pfizer enrolls first patient in phase III sickle cell disease trial

Thursday, June 25, 2015 10:54 AM

Pfizer has announced that the first patient has been enrolled in the RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) study—a phase III clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis in hospitalized individuals with sickle cell disease who are 6 years of age or older.

More... »


Report: Innovation trends in treatments for rare diseases and widespread conditions

Wednesday, June 17, 2015 08:45 AM

The antibiotics market is at risk of losing another decade to inadequate levels of research and innovation, according to international intellectual property firm Marks & Clerk’s new report From rare to routine—medicines for rare diseases, vaccines and antibiotics. Research highlights the striking difference between research levels into rare diseases, vaccines and antibiotics across the globe.

More... »


Syndax appoints Dr. Briggs Morrison CEO, Michael Metzger president and COO

Monday, June 15, 2015 01:43 PM

Syndax Pharmaceuticals, a privately held oncology company based in Waltham, Mass., has announced that Briggs W. Morrison, M.D., is joining the company as CEO and a member of the board of directors, and Michael A. Metzger is joining the company as president and chief operating officer. Morrison joins Syndax from AstraZeneca, where he was executive vice president, global medicines development and chief medical officer. Metzger joins from Regado Biosciences, where he was president and CEO through the company's strategic merger with Tobira Therapeutics.

More... »

Teva rebuts Mylan chairman’s letter

Wednesday, June 10, 2015 11:13 AM

Erez Vigodman, Teva’s president and CEO, has responded to the June 1 letter by Mylan’s executive chairman Robert J. Coury. Vigodman addresses Courey’s accusations about Teva’s hostile takeover of Mylan and the lack of information available to stakeholders.

More... »

Pfizer launches $3M grants program to further breast cancer research

Friday, May 29, 2015 02:37 PM

Pfizer has launched a competitive, peer-reviewed grants program to support clinical research projects investigating Ibrance (palbociclib) in advanced breast cancer.

More... »

PatientsLikeMe appoints Jason Johnson executive vice president, head of R&D

Wednesday, May 27, 2015 12:15 PM

PatientsLikeMe has appointed Jason Johnson, Ph.D., executive vice president and head of R&D. Johnson leads the company's research, data science and informatics teams, which focus on analyzing and merging patient-reported and other data types to develop models of disease progression and generate new insights about disease, treatments and health. Johnson reports directly to CEO Martin Coulter.

More... »

The Global Drug-Lag Problem

Tuesday, May 26, 2015 08:00 AM

For all the advancements in medical research, certain regions of the world still wait to benefit from timely access to new drugs.

More... »

PatientsLikeMe appoints Jason Johnson executive vice president and head of R&D

Thursday, May 21, 2015 02:46 PM

PatientsLikeMe has appointed Jason Johnson, Ph.D., as executive vice president and head of R&D. Johnson leads the company's research, data science and informatics teams, which focus on analyzing and merging patient-reported and other data types to develop models of disease progression and generate new insights about disease, treatments and health. Johnson reports directly to CEO Martin Coulter.

More... »

23andMe launches Lupus research study in collaboration with Pfizer

Thursday, May 14, 2015 10:19 AM

23andMe, a personal genetics company based in Mountain View, Calif., has launched the Lupus Research Study in collaboration with Pfizer. The companies aim to enroll 5,000 individuals with systemic lupus erythematosus, more commonly known as lupus, into the study to help better understand the genetics of lupus. The effort also is in collaboration with the Lupus Research Institute and in concert with Lupus Awareness Month in May.

More... »

Pfizer acquires minority interest in AM-Pharma; secures option to acquire company

Wednesday, May 13, 2015 12:15 PM

Pfizer has acquired a minority equity interest in AM-Pharma, a privately held Dutch biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, and secured an exclusive option to acquire the remaining equity in the company.

More... »


CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs